Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease

Akshay Sharma, Haydar Frangoul, Franco Locatelli, Kevin H.M. Kuo, Monica Bhatia, Markus Y Mapara, Michael J. Eckrich, Suzan Imren, Nanxin Li, Jaime Rubin, Siyu Zhang, Tina Liu, William Hobbs, Stephan A. Grupp

Blood (2024) 144 (Supplement 1): 7453.

https://doi.org/10.1182/blood-2024-204112

Published: 2024

Journal Articles

Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Transfusion-Dependent Beta-Thalassemia

Blood (2024) 144 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2024-204115

Published: 2024

Journal Articles

Clinical Complications and Healthcare Resource Utilization in Medicaid and Commercially Insured Patients with Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions

Chuka Udeze, Michelle Jerry, Kristin Evans, Nanxin Li, Siddharth Jain, Biree Andemariam

Blood (2024) 144 (Supplement 1): 7661.

https://doi.org/10.1182/blood-2024-204008

Published: 2024

Journal Articles

Adherence, Clinical and Economic Outcomes in Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises Treated with L-Glutamine, Voxelotor, or Crizanlizumab Covered By Medicaid and Commercial Insurance in the United States

Chuka Udeze, Michelle Jerry, Kristin Evans, Nanxin Li, Siddharth Jain, Biree Andemariam

Blood (2024) 144 (Supplement 1): 7660.

https://doi.org/10.1182/blood-2024-203628

Published: 2024

Journal Articles

Improvements in Health-Related Quality of Life after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease

Akshay Sharma, Haydar Frangoul, Markus Mapara, Suzan Imren, Nanxin Li, Tina Liu, Jaime Rubin, Daoyuan Shi, William Hobbs, Stephan Grupp

Blood (2023) 142 (Supplement 1): 4999.

https://doi.org/10.1182/blood-2023-190203

Published: 2023

Journal Articles

Improvements in Health-Related Quality of Life after Exagamglogene Autotemcel in Patients with Transfusion-Dependent Beta-Thalassemia

Franco Locatelli, Peter Lang, Selim Corbacioglu, Donna Wall, Amanda M Li, Josu de La Fuente, Puja Kohli, Nanxin Li, Jaime Rubin, Siyu Zhang, Lanju Zhang, William Hobbs, Haydar Frangoul

Blood (2023) 142 (Supplement 1): 4997.

https://doi.org/10.1182/blood-2023-179916

Published: 2023

Journal Articles

Title: The Impact of Recent Vaso-Occlusive Crisis on Health-Related Quality of Life in Adults with Sickle Cell Disease

Jennifer Drahos, Adriana Boateng-Kuffour, Melanie Calvert, Ashley Valentine, Anthony Mason, Nanxin Li, Zahra Pakbaz, Farrukh Shah, Nick Ainsworth, Antony P Martin

Blood (2023) 142 (Supplement 1): 3678.

https://doi.org/10.1182/blood-2023-189699

Published: 2023

Journal Articles

Differing Definitions of Vaso-Occlusion in Clinical Studies of Sickle Cell Disease Can Result in Differing Outcomes

Haydar Frangoul, Suzan Imren, Fengjuan Xuan, Nanxin Li, Jaime Rubin, William Hobbs, Franco Locatelli

Blood (2023) 142 (Supplement 1): 7107.

https://doi.org/10.1182/blood-2023-189246

Published: 2023

Journal Articles

Clinical and Economic Outcomes in Patients with Transfusion-Dependent β-Thalassemia and Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises Receiving Hematopoietic Stem Cell Transplants in the United States

Chuka Udeze, Kristin Evans, Yoojung Yang, Timothy Lillehaugen, Janna Manjelievskaia, Urvi Mujumdar, Nanxin Li, Biree Andemariam

Blood (2022) 140 (Supplement 1): 10741–10742.

https://doi.org/10.1182/blood-2022-157601

Published: 2022

Journal Articles

Health-Related Quality of Life and Disease Impacts in Adults with Transfusion-Dependent β-Thalassemia: Preliminary Results from the Global Longitudinal Survey

Nanxin Li, Jennifer Drahos, Adriana Boateng-Kuffour, Melanie Calvert, Laurice Levine, Neelam Dongha, Zahra Pakbaz, Fikret Kaan Oran, Kamran Iqbal, Farrukh Shah, Antony P. Martin

Blood (2022) 140 (Supplement 1): 10869–10870.

https://doi.org/10.1182/blood-2022-162380

Published: 2022

Journal Articles

Health-Related Quality of Life, Disease Impacts, and Health Equity Concerns in Adults with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises: Preliminary Results from a Global Longitudinal Survey

Jennifer Drahos, Adriana Boateng-Kuffour, Melanie Calvert, Ashley Valentine, Anthony Mason, Zahra Pakbaz, Fikret Kaan Oran, Kamran Iqbal, Farrukh Shah, Nanxin Li, Antony P. Martin

Blood (2022) 140 (Supplement 1): 1387–1388.

https://doi.org/10.1182/blood-2022-157818

Published: 2022

Journal Articles

Bleeding Data across Baseline FIX Expression Levels in People with Hemophilia B: An Analysis Using the 'Factor Expression Study'

Tom Burke, Anum Shaikh, Talaha Ali, Nanxin Li, Barbara A Konkle, Declan Noone, Brian O'Mahony, Steven W Pipe, Jamie O'Hara

Blood (2021) 138 (Supplement 1): 592.

https://doi.org/10.1182/blood-2021-152551

Published: 2021

Journal Articles

Patients' and Caregivers' Preferences for Different Hemophilia a Treatment Attributes

Namita Joshi, PhD MS, BPharm, Xinyi Ng, Marc Botteman, MS, MA, Nanxin Li, Rachel Shah, BS, Nisha Jain, Nicole Lyn, Jun Su

Blood (2019) 134 (Supplement_1): 2122.

https://doi.org/10.1182/blood-2019-126774

Published: 2019

Journal Articles

Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc)

Louis M. Aledort, MD, Nisha Jain, MBBS,MD, Nanxin Li, Sangeeta Krishnan, PharmD, Benjamin Hagberg, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2018-99-114905

Published: 2018

Journal Articles

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Nanxin Li, Koo Wilson, Marc Botteman, MS, MA, Daniel Nicoloso, Sangeeta Krishnan, PharmD, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3520.

https://doi.org/10.1182/blood-2018-99-114993

Published: 2018

Journal Articles

Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data

Nanxin Li, Chelsey Yang, Liangyi Fan, Todor Totev, Annie Guerin, MSc, Lei Chen, MDPhD

Blood (2015) 126 (23): 2090.

https://doi.org/10.1182/blood.V126.23.2090.2090

Published: 2015

NARROW

Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease

Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Transfusion-Dependent Beta-Thalassemia

Clinical Complications and Healthcare Resource Utilization in Medicaid and Commercially Insured Patients with Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions

Adherence, Clinical and Economic Outcomes in Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises Treated with L-Glutamine, Voxelotor, or Crizanlizumab Covered By Medicaid and Commercial Insurance in the United States

Improvements in Health-Related Quality of Life after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease

Improvements in Health-Related Quality of Life after Exagamglogene Autotemcel in Patients with Transfusion-Dependent Beta-Thalassemia

Title: The Impact of Recent Vaso-Occlusive Crisis on Health-Related Quality of Life in Adults with Sickle Cell Disease

Differing Definitions of Vaso-Occlusion in Clinical Studies of Sickle Cell Disease Can Result in Differing Outcomes

Clinical and Economic Outcomes in Patients with Transfusion-Dependent β-Thalassemia and Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises Receiving Hematopoietic Stem Cell Transplants in the United States

Health-Related Quality of Life and Disease Impacts in Adults with Transfusion-Dependent β-Thalassemia: Preliminary Results from the Global Longitudinal Survey

Health-Related Quality of Life, Disease Impacts, and Health Equity Concerns in Adults with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises: Preliminary Results from a Global Longitudinal Survey

Bleeding Data across Baseline FIX Expression Levels in People with Hemophilia B: An Analysis Using the 'Factor Expression Study'

Patients' and Caregivers' Preferences for Different Hemophilia a Treatment Attributes

Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc)

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only